EA201992402A1 - Антитела против ilt4 и антигенсвязывающие фрагменты - Google Patents

Антитела против ilt4 и антигенсвязывающие фрагменты

Info

Publication number
EA201992402A1
EA201992402A1 EA201992402A EA201992402A EA201992402A1 EA 201992402 A1 EA201992402 A1 EA 201992402A1 EA 201992402 A EA201992402 A EA 201992402A EA 201992402 A EA201992402 A EA 201992402A EA 201992402 A1 EA201992402 A1 EA 201992402A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ilt4
binding fragments
antigen
antibodies against
antibodies
Prior art date
Application number
EA201992402A
Other languages
English (en)
Inventor
Луис А. Сунига
Барбара Джойс-Шаикх
Милан Блануша
Андреа Клаудиа Шустер
Корнелиа Шульце
Original Assignee
Мерк Шарп И Доум Корп.
Эйдженус Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп., Эйдженус Инк. filed Critical Мерк Шарп И Доум Корп.
Publication of EA201992402A1 publication Critical patent/EA201992402A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к антителам и их антигенсвязывающим фрагментам, связывающимся с ILT4 (иммуноглобулин-подобным транскриптом 4), и их комбинациям, например, с антителом против PD1. Настоящее изобретение также относится к способам их применения, например, в лечении или профилактике злокачественного новообразования у индивидуума и способам получения таких антител и фрагментов.
EA201992402A 2017-04-07 2018-04-05 Антитела против ilt4 и антигенсвязывающие фрагменты EA201992402A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483019P 2017-04-07 2017-04-07
PCT/US2018/026160 WO2018187518A1 (en) 2017-04-07 2018-04-05 Anti-ilt4 antibodies and antigen-binding fragments

Publications (1)

Publication Number Publication Date
EA201992402A1 true EA201992402A1 (ru) 2020-02-19

Family

ID=62063229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992402A EA201992402A1 (ru) 2017-04-07 2018-04-05 Антитела против ilt4 и антигенсвязывающие фрагменты

Country Status (27)

Country Link
US (4) US11053315B2 (ru)
EP (1) EP3606958A1 (ru)
JP (2) JP7045392B2 (ru)
KR (1) KR102357823B1 (ru)
CN (1) CN110719917A (ru)
AR (1) AR111362A1 (ru)
AU (3) AU2018248294B2 (ru)
BR (1) BR112019021000A2 (ru)
CA (1) CA3057378A1 (ru)
CL (1) CL2019002855A1 (ru)
CO (1) CO2019011155A2 (ru)
CR (1) CR20190459A (ru)
DO (1) DOP2019000253A (ru)
EA (1) EA201992402A1 (ru)
EC (1) ECSP19072235A (ru)
GE (2) GEAP202215209A (ru)
IL (1) IL269593A (ru)
JO (1) JOP20190236B1 (ru)
MX (1) MX392369B (ru)
NI (1) NI201900103A (ru)
PE (1) PE20191813A1 (ru)
PH (1) PH12019502275A1 (ru)
SG (1) SG11201909081YA (ru)
TN (1) TN2019000272A1 (ru)
TW (1) TWI796329B (ru)
UA (1) UA126865C2 (ru)
WO (1) WO2018187518A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
TW202428604A (zh) * 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
US20210301020A1 (en) * 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
KR20210108940A (ko) * 2018-09-17 2021-09-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 항-lilrb2 항체 및 이의 이용 방법
CN113766930B (zh) * 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
CN112442527B (zh) * 2019-08-27 2022-11-11 深圳市英马诺生物科技有限公司 孤独症诊断试剂盒、基因芯片、基因靶点筛选方法及应用
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
MX2022008216A (es) * 2020-01-02 2022-08-04 Merck Sharp & Dohme Llc Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
EP4100439A4 (en) * 2020-02-05 2024-05-29 The Board Of Regents Of The University Of Texas System NOVEL LILRB2 ANTIBODIES AND USES THEREOF
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof
KR20230058074A (ko) 2020-08-12 2023-05-02 비온드 바이오로직스 엘티디 Ilt2에 대한 항체 및 이의 용도
MX2023003186A (es) * 2020-09-17 2023-04-13 Merck Sharp & Dohme Llc Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer.
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
CA3214853A1 (en) * 2021-04-09 2022-10-13 Celidex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
MX2024001690A (es) 2021-08-05 2024-04-19 Immunos Therapeutics Ag Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
US20250044295A1 (en) * 2021-12-16 2025-02-06 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
US20250197491A1 (en) 2022-03-11 2025-06-19 Macomics Limited Compositions and methods for modulation of macrophage activity
CA3246509A1 (en) * 2022-03-28 2023-10-05 Coherus Biosciences, Inc. ANTI-ILT4 COMPOSITIONS AND METHODS
KR20250006251A (ko) * 2022-04-29 2025-01-10 머크 샤프 앤드 돔 엘엘씨 항-ilt4 항체 또는 그의 항원-결합 단편의 제약 제제 및 사용 방법
AU2023259126A1 (en) * 2022-04-29 2024-10-31 Merck Sharp & Dohme Llc Stable formulations of anti-ilt4 antibodies or antigen-binding fragments thererof in combination with anti-pd-1 antibodies and methods of use thereof
CN116333128B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望（蘇州）生物醫藥科技有限公司 抗lilrb2抗體及其用途
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
WO2024041315A1 (en) * 2022-08-22 2024-02-29 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-lilrb2 antibodies and uses thereof
JP2025532504A (ja) 2022-09-08 2025-10-01 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｉｌｔ４抗体及びその医薬的使用
WO2024120526A1 (zh) 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
CN120548326A (zh) * 2022-12-23 2025-08-26 艾奥麦克斯治疗公司 靶向白细胞免疫球蛋白样受体亚家族b1（lilrb1）和lilrb2的交叉特异性抗原结合蛋白（abp）、其组合和用途
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2558160T3 (es) 1998-12-09 2016-02-02 Phyton Holdings, Llc Glicoproteínas que tienen glicosilación de tipo humano
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002345878A1 (en) 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
EP1453540A4 (en) 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
DE102004034416A1 (de) 2004-07-15 2006-02-02 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Flüssige, strahlunghärtende Zusammensetzungen
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
TW201247700A (en) 2011-05-05 2012-12-01 Baylor Res Inst Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
EP4721752A2 (en) 2011-12-30 2026-04-08 Cellscript, Llc Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2014006063A2 (en) 2012-07-02 2014-01-09 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
JP5858411B2 (ja) 2012-12-28 2016-02-10 国立大学法人大阪大学 コラーゲン結合性分子を付加した改変ラミニンおよびその利用
US10138286B2 (en) * 2013-03-12 2018-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
KR20170007449A (ko) * 2014-05-22 2017-01-18 프레드 헛친슨 켄서 리서치 센터 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US20170274003A1 (en) 2014-09-16 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016127247A1 (en) 2015-02-11 2016-08-18 University Health Network Methods and compositions for modulating lilr proteins
AU2016229201B2 (en) * 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
WO2018013534A1 (en) 2016-07-11 2018-01-18 Dana-Farber Cancer Institute, Inc. Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
WO2018022881A2 (en) 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CA3000514A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
WO2018035503A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
MX2019003462A (es) 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體

Also Published As

Publication number Publication date
AU2018248294B2 (en) 2021-08-05
US11053315B2 (en) 2021-07-06
WO2018187518A1 (en) 2018-10-11
JOP20190236B1 (ar) 2023-09-17
UA126865C2 (uk) 2023-02-15
KR20190136064A (ko) 2019-12-09
AU2018248294A1 (en) 2019-10-10
TW201839014A (zh) 2018-11-01
ECSP19072235A (es) 2019-12-27
MX392369B (es) 2025-03-24
US20240228614A1 (en) 2024-07-11
TN2019000272A1 (en) 2021-01-07
CL2019002855A1 (es) 2020-02-21
DOP2019000253A (es) 2019-12-15
US20220002403A1 (en) 2022-01-06
US11897957B2 (en) 2024-02-13
PE20191813A1 (es) 2019-12-26
KR102357823B1 (ko) 2022-01-28
JP7045392B2 (ja) 2022-03-31
CR20190459A (es) 2020-02-14
CN110719917A (zh) 2020-01-21
CO2019011155A2 (es) 2019-10-21
TWI796329B (zh) 2023-03-21
GEP20227440B (en) 2022-11-25
CA3057378A1 (en) 2018-10-11
AU2021225143A1 (en) 2021-09-30
US11897956B2 (en) 2024-02-13
JP2022084773A (ja) 2022-06-07
US20180298096A1 (en) 2018-10-18
AU2024278314A1 (en) 2025-01-09
PH12019502275A1 (en) 2020-09-21
US12344670B2 (en) 2025-07-01
EP3606958A1 (en) 2020-02-12
IL269593A (en) 2019-11-28
BR112019021000A2 (pt) 2020-05-05
MX2019011927A (es) 2020-02-10
SG11201909081YA (en) 2019-10-30
US20220033496A1 (en) 2022-02-03
NI201900103A (es) 2019-10-31
AR111362A1 (es) 2019-07-03
JOP20190236A1 (ar) 2019-10-06
JP7394160B2 (ja) 2023-12-07
JP2020519235A (ja) 2020-07-02
GEAP202215209A (en) 2022-07-11

Similar Documents

Publication Publication Date Title
EA201992402A1 (ru) Антитела против ilt4 и антигенсвязывающие фрагменты
CR20200467A (es) Agentes anticuerpos anti-cd25
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202092847A1 (ru) Антитела к cd3 и их применение
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
MX2024005811A (es) Inmunoglobulinas de enlace a tgf?1 y usos de las mismas.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202090791A1 (ru) Агонистические антитела против cd40
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2019000963A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
MX2020008768A (es) Agentes anticuerpos anti-cd25.
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения